MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • MDS Virtual Congress 2020

    Relationship Between a-syn RT-QuIC and a-syn Neuropathologic Burden in Dementia with Lewy Bodies

    D. Coughlin, C. Orru, B. Groveman, A. Hiniker, R. Rissman, B. Caughey, D. Galasko (San Diego, CA, USA)

    Objective: To determine if measures of alpha-synuclein (a-syn) real time quaking induced conversion (RT-QuIC) activity are related to a-syn neuropathologic burden in dementia with Lewy…
  • MDS Virtual Congress 2020

    Intrastriatal injection of alpha-synuclein preformed fibrils results in cognitive dysfunction and L-DOPA reversible sensorimotor impairments in rats

    S. Fleming, J. Patterson, L. Yan, C. Kemp, K. Miller, A. Stoll, M. Duffy, D. Herman, J. Lipton, K. Luk, J. Goudreau, C. Sortwell (Rootstown, OH, USA)

    Objective: To determine the effect of intrastriatal injection of alpha-synuclein (aSyn) preformed fibrils (PFFs) on sensorimotor and non-motor function in rats. Background: The ideal animal…
  • MDS Virtual Congress 2020

    Selective α-synuclein overexpression-induced pathology in noradrenergic neurons: a new mouse model for prodromal Parkinson’s disease?

    B. Lee, Y. Chen, G. Ganjam, N. Decher, A. Gundlfinger, W.J Berg, M. Britschgi, O. Oertel (Marburg, Germany)

    Objective: To investigate the phenotype of noradrenergic (NA) neurons in an animal model with selective overexpression of α-synuclein (αSyn) in the locus coeruleus (LC) with…
  • MDS Virtual Congress 2020

    Characterization of novel alpha-synuclein aggregation model of Parkinson’s disease

    A. Singh, S. Reunanen, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

    Objective: To establish and characterize a robust alpha-synuclein (aSyn) aggregation pathology research model to allow efficient drug development platform for Parkinson's disease (PD). Background: PD…
  • MDS Virtual Congress 2020

    Unraveling the role of amylin oligomers in synucleinopathies

    I. Martinez Valbuena, R. Valenti Azcarate, C. Caballero, I. Marcilla Garcia, I. Amat-Villegas, J. Sanchez, G. Marti-Andres, L. Armengou, M.R Luquin Piudo (Pamplona, Spain)

    Objective: The aim of this work is to elucidate the role of amylin in both alpha-synuclein amyloid formation and Parkinson’s disease (PD) and dementia with…
  • MDS Virtual Congress 2020

    The Fragile X Mental Retardation Protein is lost prior to the appearance of Lewy pathology in Parkinson’s disease

    T. Koeglsperger, Y. Tan, C. Sgobio, T. Arzberger, F. Machleid, Q. Tang, E. Findeiss, J. Tost, T. Chakroun, P. Gao, M. Höllerhage, K. Bötzel, J. Herms, G. Höglinger (Evry Cedex, France)

    Objective: The degeneration of dopaminergic (DA) substantia nigra pars compacta (SNc) neurons is a pathological hallmark of Parkinson's disease (PD). Cell death in PD is…
  • MDS Virtual Congress 2020

    Biomarkers for Parkinson´s Disease with Reflex Tears Correlate with Disease Duration

    M. Lew, S. Janga, D. Feigenbaum, D. Freire, M. Edman, W. Mack, C. Okamoto, S. Hamm-Alvarez (Los Angeles, CA, USA)

    Objective: To determine if the protein composition of reflex tears differs in Parkinson’s disease (PD) patients stratified by disease duration compared to Healthy Controls (HC).…
  • MDS Virtual Congress 2020

    Identification and characterization of anti-prionic compounds that disassemble αSyn prions as a novel therapeutic approach for synucleinopathies

    D. Willbold, M. Sevenich, W. Hoyer, J. Mohrlüder, A. Willuweit (Jülich, Germany)

    Objective: Stabilization of monomeric α-synuclein protein (αSyn) by transient and high-affinity binding ligands is a novel and highly innovative anti-prionic treatment strategy for synucleinopathies .…
  • MDS Virtual Congress 2020

    Development and Characterization of an Ultrasensitive Assay Platform for Detection of PD Associated alpha-Synuclein Oligomers in Human Blood

    D. Robakis, A. Chiu, B. Chang, R. Rubenstein (Brooklyn, NY, USA)

    Objective: To develop a sensitive, specific and consistent detection of a-SynO in biofluids to provide a reliable biomarker for disease diagnosis, progression, and a theranostic…
  • MDS Virtual Congress 2020

    miRNA sequencing from routine colonic biopsies reveals an enrichment of submucosal hsa-miRNA-486-5p in Parkinson’s disease

    A. Kurz, R. Kumar, C. Wenk, B. Nordhoff, J. Schirra, S. Donakonda, G. Höglinger, K. Bötzel, L. Holdt, T. Koeglsperger (Munich, Germany)

    Objective: In the present work, we aimed to investigate the expression of microRNAs (miRNAs) in routine colonic biopsies obtained from patients with idiopathic Parkinson's disease…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 51
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley